CY2019004I2
(el )
2019-11-27
Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0819165A2
(pt )
2015-06-23
Anticorpos anti-vegf
BRPI0907237A2
(pt )
2015-07-14
Anticorpo anti-cldn6
HRP20171011T1
(hr )
2017-09-22
ANTI-eMET ANTITIJELO
DK2344537T3
(da )
2014-02-10
Bispecifikke anti-vegf/anti-ang-2-antistoffer
BRPI0907532A2
(pt )
2015-07-28
Anticorpos anti-c5ar humanizados
IL212175B
(en )
2019-08-29
Muc1* antibodies
PT2376116E
(pt )
2016-02-24
Anticorpos anti-igf
BRPI0906877A2
(pt )
2015-07-28
Anticorpos anti-trkb aperfeiçoados
HUE056626T2
(hu )
2022-02-28
Antitestkészítmény
DK2131860T3
(da )
2014-01-13
Anti-sclerostin-antistoffer
PT2195026E
(pt )
2014-03-31
Anticorpos anti-esclerostina
EP2337798A4
(en )
2012-10-24
SPECIFIC ANTIBODIES OF THE ASB
EP2358392A4
(en )
2012-08-29
ANTIBODY FORMULATION
DK2459167T3
(da )
2013-06-03
SUBKUTAN ANTI-HER2-antistofformulering
PT2406284T
(pt )
2016-09-29
Anticorpos anti-bcma
PL3059246T3
(pl )
2018-11-30
Zmodyfikowany region stały przeciwciała
BRPI0922800A2
(pt )
2015-12-22
anticorpos c-met
BRPI1011145A2
(pt )
2016-03-15
anticorpo anti-axl
CR20170001A
(es )
2017-08-10
Anticuerpos anti factor d humanizados
EP2482848A4
(en )
2013-04-17
Endoglin antibodies
BRPI0820298A2
(pt )
2017-04-04
anticorpos anti-vegf composições e métodos
EP2473531A4
(en )
2013-05-01
Anti-gitr antibodies
BRPI0912173A2
(pt )
2016-07-26
anticorpos anti-flt3
BRPI0909633A2
(pt )
2015-09-22
anticorpos anti-tyrp1